YARW
Yarrow·NASDAQ
--
--(--)
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About YARW
Yarrow Bioscience, Inc.
Natural plant-based pharmaceutical raw materials, herbal extract manufacturers
Chemical and pharmaceutical
--
01/25/2018
NASDAQ Stock Exchange
10
12-31
Common stock
470 James Street, Suite 007, New Haven, CT 06513
Develops therapies for chronic inflammatory and immune-mediated conditions.
Yarrow Bioscience, Inc., was incorporated in October 2011 as a Delaware corporation. The company is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat inflammatory and immune-mediated diseases with high unmet medical needs. Yarrow's proprietary BET inhibitors (which make up its InhiBET platform) are designed to overcome the limitations of early stage BET inhibitors by utilizing alternative routes of administration and enhancing selectivity. The company is also focused on developing therapies for autoimmune thyroid diseases, including a potentially pioneering monoclonal antibody against the thyroid stimulating hormone receptor, which is designed to directly disrupt the central mechanism of Graves' disease and thyroid eye disease.
Company Financials
EPS
YARW has released its 2026 Q2 earnings. EPS was reported at -2.14, versus the expected -11, beating expectations. The chart below visualizes how YARW has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
YARW has released its 2026 Q2 earnings report, with revenue of 97.00K, reflecting a YoY change of 40.58%, and net profit of -3.01M, showing a YoY change of 47.75%. The Sankey diagram below clearly presents YARW's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
